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Abstract
Purpose: Magnetic resonance enterography (MRE) is a
useful tool in assessing the transmural and extraintestinal
lesions in Crohn’s disease (CD). However, the influence
of anti-tumor necrosis factor (anti-TNF) therapy on
MRE features of CD severity remains unknown. The
purpose of the study was to assess the short- and long-
term changes in MRE features of CD activity in relation
to CD clinical course in patients treated with anti-TNF
antibodies.
Methods: The influence on the most important param-
eters of CD activity seen in MRE was assessed retro-
spectively using a validated score. Patients were treated
with anti-TNF agents and the clinical, laboratory, and
MRE CD activity was estimated at baseline, after the
induction therapy and after 1 year of treatment.
Results: 71 patients were enrolled in a study. The change in
CD clinical activity correlated significantly with fluctua-
tions in MRE activity score (P < 0.0001, r = 0.5 for
induction; P = 0.004, r = 0.7 for maintenance anti-TNF
therapy, respectively). Bowel wall thickening, mesenteric
lymphadenopathy, and fat wrapping with vascular prolif-
eration wereMRE parameters which changed significantly
both after the induction and maintenance treatment in
patients responding to the therapy. The change in MRE
activity score was mostly pronounced during the first
3 months of treatment,when compared to the continuation
of the therapy till week 52–54 (-6 points vs. -2 points,
respectively; P = 0.0008).
Conclusions: Transmural and extraintestinal healing seen
in MRE correlates with changes in CD clinical activity
during anti-TNF therapy, thus MRE seems to be a useful
tool in monitoring the efficacy of biological agents.
Key words: Anti-tumor necrosis factor alpha
therapy—Crohn’s disease—Magnetic resonance
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In recent years, magnetic resonance enterography (MRE)
has become one of the most important diagnostic methods
in the assessment of Crohn’s disease (CD) activity [1]. Due
to its non-invasiveness, it can be performed multiple times
in the same patient, what enables the dynamic estimation of
disease progression or regression in time [2].
Anti-tumor necrosis factor alpha (anti-TNF) anti-
bodies are novel potent anti-inﬂammatory drugs in CD
[3]. Nevertheless, it is still a matter of debate, how to
monitor the course of anti-TNF therapy. Endoscopy is
believed to be a gold standard; however, due to its
invasiveness it is questionable to repeat this investigation
in a short period of time in all patients [3]. That is why it
seems that MRE could be a valuable alternative for
endoscopic assessment, and in the case of small bowel
CD—even a method of choice for dynamic monitoring of
the course of anti-TNF therapy. Moreover, MRE also
seems to be the most accurate tool in determining so
called transmural healing in CD, as it allows to visualize
all layers of the gut wall [4]. However, taking into ac-
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extraintestinal CD manifestations in MRE, there are still
few data concerning the direct influence of anti-TNF
therapy on radiological parameters of CD activity. That
is why, due to an increasing role of MRE in diagnostics
of CD, there is an urgent need to determine which
morphological changes in the inflamed intestines result
from anti-TNF therapy. This could help in a better
understanding of the mechanisms of the action of bio-
logical agents, and it would provide important data on
the definition of transmural and extraintestinal healing,
as there are still many difficulties in defining this phe-
nomenon. Thus, the main aim of the current study is to
assess which radiological features of CD severity in MRE
are mostly influenced by anti-TNF antibodies in relation
to the efficacy of biological therapy.
Patients and methods
We retrospectively analysed data from patients with
diagnosed CD, who were treated with anti-TNF agents in
years 2009–2014 in our department. All patients were
treated according to the current therapeutic guidelines
with either adalimumab (ADA) or inﬂiximab (IFX) [5].
ADA was administered in the following doses: 160 mg at
week 0, 80 mg at week 2, 40 mg every other week till week
12 (7 induction doses), and then in patients responding to
induction therapy—40 mg every other week till week 52.
IFX was administered in the doses of 5 mg/kg body
weight at week 0, 2, 6 (3 induction doses), and then in
patients responding to induction therapy—every 8 weeks
till week 52. Response to the induction therapy was de-
fined clinically as a decrease in Crohn’s Disease Activity
Index (CDAI) by 100 points or more. Clinical remission
was defined as CDAI < 150 points [6].
The inclusion criteria were as follows:
1. Qualification for biological therapy because of CD flare
(as assessed by CDAI) not responding to standard
medical therapy. Standard medical therapy was defined
as therapeutic and stable doses of steroids (1 mg of
prednisolone/kg body weight) for at least 3 weeks, and/
or azathioprine (AZA—2–2.5 mg/kg body weight),
and/or mesalamine (4 g daily) for at least 12 weeks.
2. Ileal or ileocolonic CD location.
3. Performance of MRE twice: at baseline—up to
3 weeks before starting anti-TNF therapy, and after
induction doses of biological agents: at week 12–14 in
the case of ADA and at week 9–12 in the case of IFX.
Only MRE investigations performed with the same
protocol were taken into account. When possible, also
MRE studies performed after 1 year of anti-TNF
therapy were analysed.
Exclusion criteria:
1. Isolated colonic CD.
2. Significant changes in therapeutic regimens of anti-
TNF therapy defined above or in the concomitant
treatment, like for example, the introduction of a new
drug, a change in the dose of immunosuppressant.
Only tapering of steroids after finishing the induction
phase of anti-TNF therapy or discontinuation of
antibiotics were allowed in patients responding to the
biological treatment.
3. Previous anti-TNF therapy <12 weeks before enrol-
ment to the current analysis.
Clinical activity was assessed by CDAI. The severity
of endoscopic lesions was estimated by calculating Sim-
ple Endoscopic Score for Crohn’s Disease (SES-CD) [7].
Both SES-CD and CDAI were calculated prospectively.
Biochemical activity was assessed in parallel.
MRE studies were performed with the same protocol
as described previously [8]. Patients fasted for 6 h before
MRE. 30–40 min before scanning, patients were admin-
istered 1500 ml of oral polyethylene glycol. Fifteen min-
utes before the procedure, 40 mg of buscolysin was
injected intravenously in order to reduce bowel motility.
The study protocol consisted of the following sequences:
1. true fast imaging with steady-state free precession
sequences in the coronal and transverse planes,
2. single-shot turbo spin-echo sequences with fat sup-
pression in the coronal plane,
3. cine loop coronal images for the visualization of the
bowel movements and stenosis,
4. fat-suppressed 3D T1-weighted Volumetric Interpo-
lated Breath-Hold Examination and T1-weighted 3D
Fast Low Angle Shot technique before and three
times—30, 90 s, and 5 min—after intravenous injec-
tion of gadolinium contrast (dose of 0.1 mmol/kg
body weight followed by 20 ml of saline).
All MRE investigations were assessed by a radiologist
with more than 12 years of experience in this cross-sec-
tional imaging technique. All studies were blinded for the
radiologist and then randomly analysed and quantiﬁed
using the grading score called the Simple Enterographic
Activity Score for Crohn’s Disease (SEAS-CD), whose
diagnostic utility was previously proved in an independent
cohort of CD patients by Eder et al. [8]. This score consists
of the most important features reflecting CD activity,
which were quantified depending on their intensity and
they formed the final SEAS-CD result (Table 1).
As the ﬁrst step, we determined the inﬂuence of
induction doses of anti-TNF agents on CD activity as-
sessed in MRE. We compared changes in the most
important radiological features of CD activity in patients
who responded to the therapy (deﬁned as a decrease in
CDAI by 100 points—the responders group) with pa-
tients who were primary non-responders. Then the
inﬂuence of long-term anti-TNF therapy was also anal-
ysed by comparing MRE results after induction doses of
biological agents with MRE CD activity scores after
1 year (at week 52–54) of treatment.
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Statistical analysis
Data are presented as means with standard deviations
(SD). Correlation analyses between selected parameters
were performed with the use of Spearman’s rank corre-
lation coefﬁcient. Statistical differences were calculated
using Student t test (parametric) when conditions of
normality and equal variance were met. When the nor-
mality test failed, the Wilcoxon test or Mann–Whitney
test was used for paired or unpaired groups, respectively.
A P value < 0.05 was considered significant. All data
were analysed using the GraphPad Prism Version 6.0
(GraphPad Software Inc., USA).
Results
71 CD patients, in whom MRE imaging was performed
before and after induction anti-TNF therapy, were en-
rolled into the study. Baseline characteristics of the
whole study group are presented in Table 2.
Anti-TNF induction therapy
53 patients (75%) were primary responders, whereas 18
(25%) did not respond to the induction doses of anti-
TNF antibodies. The change in CDAI scores in the
whole study group (n = 71) correlated significantly with
fluctuations in SEAS-CD scores during induction anti-
TNF therapy (Fig. 1).
In the responders group there was a signiﬁcant de-
crease in CDAI: 272 ± 90 vs. 94 ± 54 points (P <
0.0001), as well as a significant reduction of CD activity
assessed in MRE—SEAS-CD decreased from 14 ± 5
to 8 ± 4 points (P < 0.0001) (Fig. 2A). We noted
also a statistically significant change in high sensitive C-
reactive protein (hsCRP) concentration—17.3 ± 25.6
vs. 3.6 ± 4.3 mg/l (P < 0.0001), hematocrit—37 ± 5 vs.
39 ± 5% (P = 0.01), hemoglobin concentration—12.2 ±
1.9 vs. 13.1 ± 1.8 g/dl (P = 0.001), platelet count—357 ±
105 vs. 302 ± 76 103/mm3 (P < 0.0001), and erythrocyte
sedimentation rate—27 ± 19 vs. 19 ± 17 mm/h (P =
0.001).
Almost all parameters of MRE CD activity decreased
signiﬁcantly after induction anti-TNF therapy in the
Table 1. Simple Enterographic Activity Score for Crohn’s Disease (SEAS-CD) [8] All variables are calculated separately for jejunum and ileum, and
in the next step they are summed up
MRE feature Grading scale
Bowel wall thickening <3 mm: 0 pts 3–7 mm: 1 pt >7 mm: 2 pts
Contrast enhancement None: 0 pts Homogenous pattern: 1 pt Layered pattern: 2 pts
Fat wrappinga None: 0 pts Present: 1 pt
Proliferation of mesenteric
vasculaturea
None: 0 pts <5 vessels/3 cm2 of mesenteric fat: 1 pt ‡5 vessels/3 cm2 of mesenteric fat: 2 pts
Mesenteric lymphadenopathy None: 0 pts <10 enlarged (diameter > 5 mm)
lymph nodes: 1 pt
‡10 enlarged (diameter > 5 mm) lymph
nodes: 2 pts
Bowel wall ulcerations None: 0 pts At least one ulceration present, not
exceeding ½ of bowel thickness: 1 pt
At least one ulceration present,
exceeding ½ of bowel thickness:
2 pts
Stenotic complications None: 0 pts Stenosis without prestenotic dilatation: 1 pt At least one stenosis with prestenotic
dilatation: 2 pts
Intra-abdominal fistulas None: 0 pts At least one intra-abdominal fistula tract visible: 5 pts
Extent of the disease in
jejunum or ileum
<1500 mm: 1 pt >1500 mm: 2 pts
Scoring of each parameter is presented in bold
aFat wrapping and proliferation of mesenteric vasculature scores were summed up, as those phenomena are strictly interrelated and they are assessed
together
Table 2. Baseline characteristics of the whole study group (n = 71).
Data are presented as means with standard deviations (SD)
Feature
Age (years) 30 ± 9
Male/female—n 32/39
Simple Enterographic Activity Score
for Crohn’s Disease
14 ± 5
Disease duration (years) 5 ± 3
High sensitivity C-reactive protein (mg/l) 19.7 ± 25.3
Erythrocyte sedimentation rate (mm/h) 29 ± 19
Hemoglobin (g/dl) 11.9 ± 2.1
White blood cell count (103/mm3) 7.1 ± 3.5
Platelets (103/mm3) 367 ± 112
Crohn’s Disease Activity Index 273 ± 89
Simple Endoscopic Score for Crohn’s
Disease (n = 31)
13 ± 8
Disease location—n (%)
L1 (ileal) 28 (39%)
L3 (ileocolonic) 43 (61%)
Disease behavior—n (%)
B1 (inflammatory) 54 (76%)
B2 (stricturing) 5 (7%)






Previous anti-TNF therapy 9 (13%)
Anti-TNF agent used: adalimumab/
infliximab—n (%)
28/43 (39%/61%)
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responders group (Fig. 3A). Figure 4 shows examples of
the influence of induction anti-TNF therapy on selected
features of CD inflammatory activity seen in MRE
among primary responders.
In the non-responders group CDAI did not change
signiﬁcantly after anti-TNF induction therapy: 275 ± 71
vs. 212 ± 77 points. Mean SEAS-CD values only slightly
decreased in the course of biological therapy—15 ± 5 vs.
14 ± 5 points (Fig. 2B); however, taking into account
the different distribution of variables before and after
treatment, it reached the statistical significance
(P = 0.02).
In the non-responders group, we also noted a statis-
tically signiﬁcant change in hsCRP concentration—27.1 ±
23.4 vs. 17.3 ± 27.7 mg/l (P = 0.04), platelet count—401 ±
130 vs. 349 ± 95 103/mm3 (P = 0.01), and white blood cell
count—6.5 ± 3.3 vs. 5.7 ± 2.7 103/mm3 (P = 0.03). Other
laboratory parameters did not change significantly.
There was a signiﬁcant decrease only in fat wrapping
and vascular proliferation after anti-TNF induction
therapy in patients who did not respond to the treatment.
Other parameters did not change or decreased without
achieving statistical signiﬁcance (Fig. 3B).
Comparison of SEAS-CD between responders
and non-responders group
Baseline SEAS-CD scores were not statistically different
when compared the responders and non-responders
group (14 ± 5 vs. 15 ± 5 points, respectively; P = 0.09).
All assessed parameters of MRE CD activity were
comparable between the two aforementioned groups.
After ﬁnishing the induction phase of anti-TNF
therapy, SEAS-CD among non-responders was signiﬁ-
cantly higher when compared with the responders group
(14 ± 5 vs. 8 ± 4 points, respectively; P < 0.0001). Al-
most all parameters of MRE CD activity were signifi-
cantly higher among non-responders after induction
doses of anti-TNF antibodies (Fig. 5).
One-year anti-TNF therapy
In 17 patients, MRE investigation was performed three
times: at week 0, after anti-TNF induction therapy, and
after 1 year of treatment. When compared CDAI and
SEAS-CD scores after biological induction therapy and
after 1 year of treatment, changes in those parameters
correlated signiﬁcantly (P = 0.004; r = 0.7). In this
subgroup of patients—13 of them were in clinical
remission (CDAI < 150) at week 52–54 of biological
therapy; 4 patients were secondary non-responders
(CDAI ‡ 150).
In patients with a long-term remission, there was a
further, statistically signiﬁcant improvement in CDMRE
activity observed: SEAS-CD decreased from 9 ± 4
points after induction therapy to 5 ± 3 points at week
52–54 (P = 0.02). The decrease in SEAS-CD score was
mainly due to further reduction in bowel wall thickening
(P = 0.01), mesenteric lymphadenopathy (P = 0.03),
and fat wrapping with vascular proliferation (P = 0.05,
borderline significance). Other assessed MRE features
did not change or improved without statistical signifi-
cance.
Fig. 2. The change in the
Simple Enterographic
Activity Score for Crohn’s
Disease (SEAS-CD) in the
responders (A) and non-
responders (B) group after
induction anti-tumor
necrosis factor therapy.
Data are presented as
means with standard
deviations.
Fig. 1. The correlation between the change in the Crohn’s
Disease Activity Index (CDAI) and Simple Enterographic
Activity Score for Crohn’s Disease (SEAS-CD) during the
induction anti-tumor necrosis factor therapy.
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In the subgroup of secondary non-responders, SEAS-
CD increased from 6 ± 3 points to 10 ± 3 points; how-
ever, without statistical signiﬁcance. All MRE features of
CD activity assessed by SEAS-CD score increased after
1-year anti-TNF therapy without achieving statistical
signiﬁcance.
Discussion
Objective assessment of the inﬂuence of anti-TNF ther-
apy on the inﬂammatory activity of CD seems to be
crucial for the proper monitoring of the treatment out-
comes [9]. There are only few studies assessing the ability
Fig. 3. The change in the parameters of Crohn’s disease
activity assessed in magnetic resonance enterography after
induction anti-tumor necrosis factor alpha therapy in the
responders group (A) and non-responders group (B). Data
are presented as means with standard deviations.
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of magnetic resonance (MR) imaging techniques to
determine the transmural and extraintestinal healing in
CD patients treated with anti-TNF agents. First data in
this subject concerned MR techniques that were similar,
but methodologically different than MRE. Tielback et al.
showed in their retrospective analysis including 50 CD
patients that the inflammatory scores assessed in MR
imaging improved only in individuals, who responded to
the therapy [10]. Van Assche and colleagues performed a
multicentre prospective trial, in which magnetic reso-
nance enteroclysis was performed at baseline of anti-
TNF treatment, and then at week 2 and 6 months after
starting infliximab [11]. Finally, 15 patients were assessed
at weeks 2 and 26. The analysis revealed that a decrease
of the activity of inflammatory components occurred
from 2 weeks after beginning of the therapy. At week 26,
Fig. 4. A T2-weighted sequence showing thickening of bo-
wel wall before anti-tumor necrosis factor therapy (A). Dy-
namic contrast enhanced T1-volume interpolated gradient-
echo sequence showing thickening of the bowel wall with
layered enhancement, fat wrapping with a proliferation of
mesenteric vasculature (B) and with enlargement of mesen-
teric lymph nodes before starting biological treatment (C). B
T2-weighted sequence showing a significant decrease of
bowel wall thickening after induction anti-tumor necrosis fac-
tor therapy (D). Dynamic contrast enhanced T1-volume
interpolated gradient-echo sequence showing a significant
decrease of bowel wall thickening without pathological
enhancement, fat wrapping with a proliferation of mesenteric
vasculature are not present after finishing induction biological
treatment (E). The diameter of enlarged mesenteric lymph
nodes decreased significantly after the therapy (F).
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the magnetic resonance enteroclysis index improved in
80% of patients; however, only in 13% of them a com-
plete absence of CD activity was noted.
In the most recent study performed by Ordas et al.,
the accuracy of MRE in determining the clinical response
and mucosal healing in CD patients treated with anti-
TNF agents were assessed for the ﬁrst time [12]. This was
a prospective multicentre study in which 48 patients were
included, and they underwent ileocolonoscopy (as a
reference standard) and MRE at baseline and 12 weeks
after starting corticosteroids or anti-TNF therapy. The
analysis revealed that the change in the MRE activity
estimated with the use of Magnetic Resonance Index of
Activity (MaRIA) determined with 90% accuracy the
mucosal healing effect and with 83% accuracy—the
endoscopic remission [13].
To the best of our knowledge, our study is the second
one in which the utility of MRE in reﬂecting the inﬂuence
of anti-TNF therapy on CD activity was assessed, and it
includes the largest cohort of CD patients so far. Our
analysis revealed that MRE CD activity changes in
parallel with ﬂuctuations of CD clinical activity during
both—the induction (short-term) and 1-year (long-term)
anti-TNF therapy. Almost all parameters assessed rou-
tinely in MRE are improving in patients clinically
responding to the therapy in parallel to the majority of
the laboratory results. Only intraabdominal ﬁstulas were
still present after treatment, what is to be expected, as
this structural complication of CD is rather an indication
for surgery [14]. However, in rare cases other therapeutic
options are chosen, as not all patients accept surgery.
The second and more frequent scenario is that patients
underwent intestinal resection in the past and surgery has
to be avoided in order to prevent irreversible complica-
tions after multiple intestinal resections, like for example,
the short bowel syndrome. That is why some minor
proportion of CD patients with intraabdominal fistulas
is treated non-surgically, and anti-TNF therapy seems to
be the most effective choice in these cases [14].
Although statistical analysis showed, that SEAS-CD
decreased also in the non-responders group, this change
was signiﬁcantly less pronounced when compared with
patients with CDAI-100 response. The decrease in
SEAS-CD in patients not responding to the therapy was
a consequence of a slight improvement in the minority of
SEAS-CD variables; only fat wrapping with vascular
proliferation decreased signiﬁcantly. However, compar-
ison of SEAS-CD scores after the induction anti-TNF
therapy shows a signiﬁcant and very pronounced differ-
ence between responders and non-responders group.
Moreover, the majority of MRE variables differ signiﬁ-
cantly in these two groups of patients after the induction
therapeutic period (Fig. 5), what shows that SEAS-CD
reliably reflects the course of CD during biological
therapy.
Nevertheless, considering only the non-responders
group, anti-TNF treatment leads to transmural and
extraintestinal healing to some extent, as well as there is
Fig. 5. The differences in the variables assessed in mag-
netic resonance enterography after the induction phase of
anti-tumor necrosis factor alpha therapy between the
responders group and patients primarily not responding to
treatment. Data are presented as means with standard devi-
ations.
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also some improvement in single laboratory tests. How-
ever, these phenomena are insufﬁcient to be reﬂected by
regression of CD clinical activity. This is a very inter-
esting phenomenon which was conﬁrmed even on a
molecular level. In the study by Leal et al. it was shown
that also in patients not responding to the anti-TNF
therapy, a big amount of inﬂammatory parameters in-
volved in CD pathogenesis signiﬁcantly decreased, al-
though this was not reﬂected by the improvement of
clinical status of the patients [15]. These data and our
results suggest that CD symptomatology assessed by
CDAI is influenced by multiple pathogenic factors, and
only a complex, multifactorial improvement provides
clinical response.
Analysis of the long-term inﬂuence of anti-TNF
therapy also shows that changes in MRE CD activity
parameters correlate with the clinical efﬁcacy of bio-
logical agents. Comparative analysis shows that in the
case of patients achieving a long-term response to the
therapy, the degree of SEAS-CD reduction is signiﬁ-
cantly more pronounced during the ﬁrst 3 months of
treatment (induction therapy) than during maintenance
anti-TNF treatment (mean change in SEAS-CD = -6
points vs -2 points, respectively; P = 0.0008). These
data show that the strongest potential of anti-TNF
agents to induce transmural and extraintestinal healing
concerns the first, early period of treatment. Thus, it
can be hypothesized, that the degree of the healing
effect achieved during the induction anti-TNF therapy
is a predictor of further treatment’s efficacy. However,
it should be mentioned that even after 1 year of bio-
logical therapy, there was only one case of a complete
recovery from inflammatory lesions seen in MRE
(1/13–8% of patients in the long-term remission; data
not shown).
In contrast to the induction anti-TNF therapy, which
improved almost all MRE parameters of CD activity in
the responders group, further clinically successive treat-
ment results only in the signiﬁcant decrease of bowel wall
thickening, mesenteric lymphadenopathy, and fat wrap-
ping with vascular proliferation; however, these data
should be interpreted with caution due to a low number
of patients experiencing the loss of response to anti-TNF
agents. Nevertheless, it can be hypothesized that the
aforementioned MRE parameters are mostly inﬂuenced
by anti-TNF antibodies, and they are responsible to the
greatest extent for transmural and extraintestinal healing
phenomenon. The question that needs to be answered is
whether these observations could be indirectly translated
into hypotheses on the mechanisms and primary sites of
action of anti-TNF agents. This could be very prob-
lematic, however, according to the latest reports on the
pathogenesis of inﬂammatory lesions in CD, it is sug-
gested that one of the crucial roles is played by the
mesenteric adipose tissue in which signiﬁcant vascular
proliferation is seen [16]. It was hypothesized that so
called creeping fat is a potent source of pro-inflamma-
tory cytokines and other paracrine mediators, as well as
it plays a significant role in the immune response to
commensal bacteria [17]. In this hypothesis, further
transmural inflammatory lesions are a consequence of an
unusual transformation of mesenteric fatty tissue, as it
was suggested that creeping fat in CD seen in MRE, has
several features different from tissue seen in other gas-
trointestinal diseases, showing more inflammatory and
fibrous pattern [18, 19].
According to these data, we observed that a signif-
icant inﬂuence of anti-TNF antibodies, seen in all study
groups (short-term and long-term responders, as well as
among primary non-responders), concerned only the
mesenteric fatty tissue. Thus, one could hypothesize
that the primary site of action of anti-TNF antibodies is
the mesenteric creeping fat. Hypothetically, the de-
crease in the CD activity seen in MRE in terms of the
mesenteric fatty tissue in the primary non-responders
group could be an evidence, that anti-TNF antibodies
started to act, but some poorly deﬁned factors did not
allow them to lead to further transmural and extrain-
testinal healing.
Our study has several limitations. In our opinion,
the most important one is the retrospective nature of
the analysis. However, as all MRE studies were blin-
ded for the radiologist and then randomly analysed,
we believe that this methodological fact reduces the
risk of statistical bias. Another possible limitation is
the use of concomitant medicines. Although the doses
of immunosuppressive drugs were stable during the
whole observation, tapering of steroids after ﬁnishing
the induction phase of anti-TNF therapy or discon-
tinuation of antibiotics were allowed in our study. It
could be hypothesized that these facts can bias the
interpretation of the direct inﬂuence of anti-TNF
agents on CD inﬂammatory activity in MRE. How-
ever, in our real-life study group, we could not exclude
those patients, as tapering of steroids or discontinua-
tion of antibiotics is a consequence of successful
application of anti-TNF antibodies. Moreover, ster-
oids and antibiotics should not be used for a longer
period of time. There are also no data regarding the
intestinal healing effect of steroids or antibiotics in
CD. This phenomenon has been shown only for anti-
TNF agents and, to a lesser extent, for immunosup-
pressive drugs [9]. Thus, we hypothesize that the fact
of tapering the steroids or discontinuing the antibi-
otics in our study group had limited or even had no
influence on intestinal healing seen in MRE, and the
observed phenomena in imaging studies are only re-
lated to application of anti-TNF antibodies.
Another possible limitation is the used SEAS-CD
scoring system, as it assesses MRE features more on a
global level and not on a bowel segment level, as it is
done with the MaRIA system [12, 13]. This could be
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hypothetically problematic in patients in whom one
intestinal segment responds to the therapy and other
does not; however, such a situation is not likely to occur.
Nevertheless, SEAS-CD takes into account the length of
inflamed bowel loop, which is quantified and scored
separately. Moreover, SEAS-CD scoring system assesses
the CD activity (together with quantification of its ex-
tent) separately in the jejunum and ileum. That is why,
although SEAS-CD does not allow for segmental
assessment similar to MaRIA, it takes into account the
different CD locations throughout the gastrointestinal
tract and its extent in the bowel loops. Thus, it can be
even reliable in the hypothetical aforementioned situa-
tion of simultaneous response and non-response to anti-
TNF therapy in different bowel segments in the same
patient.
To conclude, in our study, we showed that MRE is a
useful tool in the assessment of CD course in patients
treated with anti-TNF agents. We conﬁrmed that trans-
mural and extraintestinal healing occurs only in indi-
viduals responding to the therapy, although, the
reduction of the inﬂammatory lesions seen in MRE takes
place to some extent also in the non-responders. The
most important compounds of the transmural and
extraintestinal healing phenomenon seem to be the bowel
wall thickening, mesenteric lymphadenopathy and
wrapping of the mesenteric fatty tissue with the vascular
proliferation. Data from our study cannot indicate the
possible primary site of action of anti-TNF antibodies
leading to intestinal healing, although the importance of
mesenteric fatty tissue is discussed. There are too few
proofs of the crucial role of creeping fat in the efﬁcacy of
biological therapy. We hypothesize, however, that our
data could be an interesting background for further
analyses on the role of mesenteric fatty tissue in anti-
TNF therapy of CD.
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